Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service

Capelle, Heloise; Tummino, C.; Greillier, L.; Gouitaa, M.; Birnbaum, J.; Ausias, Nathalie; Montana, Marc

doi:10.1111/jcpt.12645

Cited by 7 publications

(7 citation statements)

References 31 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high NPV found in our study (0.91) is consistent with that described in the literature, the latter being between 0.92-0.99, even reaching 100% true negatives in some cases [4,6,7]. Published data also indicate that in patients with false negative results subsequent reactions are usually mild, as happened with our patient [7,8].…”

Section: Discussionsupporting

confidence: 92%

“…Regarding the risk factors for HSR to platinum salts, these reactions occur after patients have undergone several courses of treatment [6,7,9]. Although we found that the median number of courses before the suspected HSR was 9, consistent with those collected in the bibliography, we did not nd statistical signi cance between the patients with positive and negative skin tests, probably due to the small sample size.…”

Section: Discussionsupporting

confidence: 64%

See 1 more Smart Citation

Value of Skin Tests for Managing Hypersensitivity Reactions to Platinum Salts

Pedraza-Nieto¹,

Beunza-Sola²,

Moreno³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Platinum-based therapy continues to be one of the pillars of the treatment of different types of cancer. However, many times the responsible clinician renounces its use after the appearance of a hypersensitivity reaction.Objective: To assess the value of skin tests (ST) in clinical practice to address the treatment of patients with suspicion of immediate hypersensitivity reactions (HSRs) to platinum salts.Methods: Single-center retrospective study performed for 3 years. Adult patients treated with any platinum salt who experienced HSR symptoms and for whom an oncologist requested ST, were included. ST with cisplatin, carboplatin and oxaliplatin were performed. Results: Twenty-two patients were included. ST were positive in 12 patients (54.5%), of which 4 (33%) presented cross-reactivity to another platinum salt. Fifteen patients continued platinum-based chemotherapy: 9 patients with positive ST (4 continued by desensitization and 5 with another platinum) and 6 patients with negative ST, of which 1 repeated an HSR. A NPV of 0.91 was calculated. Conclusion: ST allowed accurate identification of platinum allergy patients and the resumption of platinum-based therapy in many patients for whom no suitable therapeutic alternative was clinically acceptable.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 64%

Value of Skin Tests for Managing Hypersensitivity Reactions to Platinum Salts

Pedraza-Nieto¹,

Beunza-Sola²,

Moreno³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Mainly type I HSRs, IgE-mediated or not IgE-mediated, are described, while other mechanisms of hypersensitivity, mainly types III and IV, may be involved. Symptoms are variable and difficult to predict, especially in the case of other non-immunological adverse reactions, polytherapy and comorbidities [23,25,26].…”

Section: Classificationmentioning

confidence: 99%

Immune Reactions in Major Types of Oncological Treatment

Kozubek,

Wołoszczak,

Gomułka

2023

IJMS

View full text Add to dashboard Cite

In recent years, there has been a noticeable development in oncological treatment, including chemotherapy and biological treatment. Despite their significant effectiveness, they are not free from side effects, such as allergic and dermatological reactions. These reactions can vary in severity and outcome, including potential death. Examples, among others, are type I-IV hypersensitivity reactions of various origins and skin reactions including rashes, itching and redness, but also severe cutaneous syndromes. Due to the therapy used, these may include Stevens–Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome and acute generalized exanthematous pustulosis. In some cases, it is necessary to interrupt therapy, which may result in a poorer outcome and shorten the patient’s survival. This paper reviews various types of research documents published since 2016. It aims to systematize the latest knowledge and highlight the need for further research into ways to avoid adverse reactions.

show abstract

“…

We read with great interest the recent study which was conducted by Capelle et al 1 They sought to describe hypersensitivity reactions to chemotherapy regimens containing platinum and pemetrexed in patients with non-small cell lung cancer or malignant pleural mesothelioma. This study also aimed to determine the role of skin testing in confirmation of hypersensitivity reactions to the aforementioned medications in the reported case series.

…”

mentioning

confidence: 99%